CanSaRCC (Canadian Sarcoma Research and Clinical Collaboration) Sarcoma Database, Canada

Registration Status: Completed

Objective: The Canadian Sarcoma Research and Clinical Collaboration (CanSaRCC) is a growing community of clinicians and researchers across Canada united by a common interest in sarcoma and a dedication to extracting new knowledge from clinical and scientific activities. This multidisciplinary team has developed a comprehensive bioinformatics national network that will capture high quality data linked to a biorepository to improve our understanding of the biology, treatment options and patient impact for sarcoma.

Registered Biobank Name	CanSaRCC (Canadian Sarcoma Research and Clinical Collaboration) Sarcoma Database
Biobank Leader	Dr. Peter Watson, BC Cancer Tumour Tissue Repository - biobank leader for BC Cancer Victoria; Dr. Hagit Peretz Soroka, CanSaRCC Program Manager, University Health Network - biobank leader for national database
Country	Canada
Email for biobank inquiries	xiaolan.feng@bccancer.bc.ca
Principal Investigator	Dr. Xiaolan Feng - BC Cancer - Victoria biobank custodian; Dr. Christine Simmons - BC Cancer - Vancouver CanSaRCC steering committee member; Dr. Abha Gupta - Princess Margaret Cancer Centre, CanSaRCC national biobank steering committee chair
Website
User Type Mono: A biobank that supports a specific research project, may have few staff members, a small-scale accrual scope with little to no initial intention of releasing or distributing biospecimens to secondary parties Oligo: A biobank that supports several research groups or clinical trials, may or may not be designed to release biospecimens outside their collaborative group Poly: A biobank that has generally a larger accrual scope, resources, and multiple users outside the biobank proper

Biospecimen Collected:

Cohort Highlights

100 cases Next Generation Sequencing assay to detect all classes of genetic variant in Lung Cancer using a single Diagnostic test.
200 cases Colorectal TMA for QC purposes in support of study of tumor infiltrating lymphocytes in ovarian cancer tissues.
Build 300 cases breast cancer TMA containing primary tumour and matched metastatic LN for various subtypes (luminal, HER2, Triple negative). Start with Triple negatives.
125 cases Breast tumour and metastatic lymph nodes in breast cancer cases with outcomes of metastasis to lung or bone.
100 cases of rare tumours - fibrolamellar hepatocellular carcinoma. FFPE, frozen, BC.
200 cases of FFPE tissue sections from breast, lung adenocarcinoma, and lung squamous cell carcinoma with matching normal tissue (only pathology data requested).